HomeCompareRXDX vs VICI

RXDX vs VICI: Dividend Comparison 2026

RXDX yields 1.00% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $945.1K in total portfolio value
10 years
RXDX
RXDX
● Live price
1.00%
Share price
$199.92
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$106.75
Full RXDX calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — RXDX vs VICI

📍 VICI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRXDXVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RXDX + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RXDX pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RXDX
Annual income on $10K today (after 15% tax)
$85.03/yr
After 10yr DRIP, annual income (after tax)
$90.74/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, VICI beats the other by $516,178.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RXDX + VICI for your $10,000?

RXDX: 50%VICI: 50%
100% VICI50/50100% RXDX
Portfolio after 10yr
$493.7K
Annual income
$303,741.44/yr
Blended yield
61.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

RXDX
Analyst Ratings
4
Buy
7
Hold
Consensus: Hold
Price Target
$138.57
-30.7% upside vs current
Range: $67.00 — $200.00
Altman Z
94.1
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RXDX buys
0
VICI buys
0
No recent congressional trades found for RXDX or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRXDXVICI
Forward yield1.00%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$21.1K$966.2K
Annual income after 10y$106.75$607,376.13
Total dividends collected$1.0K$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$138.57$31.60

Year-by-year: RXDX vs VICI ($10,000, DRIP)

YearRXDX PortfolioRXDX Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$10,800$100.04$11,361$941.49$561.00VICI
2$11,657$100.98$13,320$1,481.32$1.7KVICI
3$12,575$101.86$16,284$2,405.01$3.7KVICI
4$13,558$102.69$21,040$4,071.78$7.5KVICI
5$14,610$103.47$29,209$7,285.49$14.6KVICI
6$15,737$104.21$44,443$14,006.51$28.7KVICI
7$16,944$104.91$75,822$29,512.55$58.9KVICI
8$18,235$105.56$148,733$69,726.75$130.5KVICI
9$19,618$106.17$344,394$189,413.75$324.8KVICI
10$21,098$106.75$966,234$607,376.13$945.1KVICI

RXDX vs VICI: Complete Analysis 2026

RXDXStock

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Full RXDX Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this RXDX vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RXDX vs SCHDRXDX vs JEPIRXDX vs ORXDX vs KORXDX vs MAINRXDX vs NNNRXDX vs EPRTRXDX vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.